RICHMOND, Va., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced that it will report its fourth quarter and full-year 2025 financial results on Thursday, February 26, 2026, at 7:00 a.m. U.S. EST. Following the release of the financial results, Joe Ciaffoni, Chief Executive Officer, and other members of Indivior’s leadership team will host a presentation via live webcast at 8:00 a.m. U.S. EST. Access to the Live Webcast Presentation: The webcast event and materia ...

RICHMOND, Va., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV), today announced completion of its redomiciliation from the United Kingdom to the United States. As a result, Indivior Pharmaceuticals, Inc., a new Delaware corporation (“IPI”), has become the new parent company. Indivior PLC is renamed Indivior Ltd. and has become a wholly-owned subsidiary of IPI. The common stock of Indivior Pharmaceuticals, Inc., is listed on Nasdaq and will continue to trade under the symbol “ ...

Core Insights - The recent tariff noise is impacting the market, and investors are advised to focus on long-term investment themes rather than reacting to headlines [1][7] Market Performance - In 2025, markets initially fell nearly 15% by April due to tariff fears, but those who remained invested saw a 39% rebound by year-end, highlighting the importance of long-term trends [2] Investment Opportunities - Investors should prioritize long-term growth opportunities, particularly in the AI sector, with trillions expected in infrastructure investments by 2030 [3] - Comfort Systems USA Inc. (NYSE:FIX) and Duke Energy Corp. (NYSE:DUK) are highlighted as stable investment options, with Duke trading at 17X forward earnings and offering a 3.7% dividend yield [4] Promising Sectors - Aerospace and defense sectors are expected to benefit from rising global military budgets, while small-cap biotech is positioned to gain from patent cliffs and M&A activity [5] - Notable companies in these sectors include L3 Harris Technology Inc. (NYSE:LHX) in defense and Indivior PLC (NASDAQ:INDV) and Day One Biopharmaceuticals Inc. (NASDAQ:DAWN) in biotech [5] Future Market Outlook - In 2026, investors who align with their risk tolerance and "follow the money" may find attractive entry points despite ongoing market volatility [6] - Current market conditions are turbulent due to renewed tariff threats, with the S&P 500 and Nasdaq 100 both sliding around 2%, marking their worst sessions in over three months [7][8]

Market Overview - U.S. stock markets ended positively with the Nasdaq Composite, Dow Jones Industrial Average, and S&P 500 gaining 1.18%, 1.08%, and 0.93% respectively despite mid-week volatility [1] - Market direction was influenced by U.S. policy developments regarding Venezuela, enthusiasm for AI-linked technology stocks, and mixed economic data [1] Economic Indicators - The manufacturing Purchasing Managers' Index (PMI) fell to 47.9 in December 2025, the lowest since October 2024, indicating contraction [2] - Conversely, the Services PMI unexpectedly rose to 54.4 in December from 52.6 in the previous month, indicating expansion [2] - Nonfarm Payrolls increased by 50,000 jobs in December, below expectations, while the unemployment rate slightly declined to 4.4% from 4.5% in November [2] - Average Hourly Earnings increased by 3.8% year-over-year, up from 3.6% in November [2] Stock Performance - Indivior PLC shares rose 21.7% since being upgraded to Zacks Rank 1 (Strong Buy) on October 31, outperforming the S&P 500's 2% increase [4] - FormFactor, Inc. shares increased by 15.9% since its upgrade to Zacks Rank 2 (Buy) on October 31, also outperforming the S&P 500 [5] - An equal-weight portfolio of Zacks Rank 1 stocks outperformed the equal-weight S&P 500 index by 7 percentage points, returning +17.81% compared to +10.85% for the index [5] Focus List and Model Portfolios - The Zacks Focus List portfolio returned +22.1% in 2025, outperforming the S&P 500 index's +17.9% gain [12] - The Focus List has consistently outperformed the S&P 500 over various time frames, including a +22.1% return in the last year compared to +17.9% for the index [14] - The Earnings Certain Admiral Portfolio (ECAP) returned -1.67% in 2025, underperforming the S&P 500's +17.9% gain [15] - The Earnings Certain Dividend Portfolio (ECDP) returned -0.6% in 2025, also underperforming compared to the S&P 500 [19] Notable Stock Recommendations - FIGS, Inc. shares surged 56.8% since being upgraded to Outperform on November 7, significantly outperforming the S&P 500's 3.5% increase [8] - Five Below, Inc. shares increased by 21.7% since its upgrade on October 29, again outperforming the S&P 500 [8] - Mettler-Toledo International Inc. and Accenture plc saw returns of 16.6% and 16.5% respectively over the past 12 weeks [14]

Financial Guidance - Indivior PLC expects total net revenue for 2026 to be in the range of $1.125 billion to $1.195 billion, with SUBLOCADE® net revenue anticipated between $905 million and $945 million [1] - The company aims to grow SUBLOCADE net revenue by 11% at the midpoint of its guidance range, while raising adjusted EBITDA by 35% and adjusted EBITDA margin by 14 percentage points [2] Business Highlights - Indivior PLC was included in the S&P SmallCap 600® index effective December 22, 2025 [3] - The company received shareholder approval to change its domicile from the U.K. to the U.S., with the new U.S. parent company, Indivior Pharmaceuticals, Inc., expected to take effect on January 26, 2026 [3] - Indivior paid off an outstanding obligation of $295 million and concluded a legacy U.S. Department of Justice matter [3] Company Overview - Indivior PLC develops, manufactures, and sells buprenorphine-based prescription drugs for treating opioid dependence, with products including Suboxone Film, Suboxone Tablet, and Subutex Tablet [4] - The company's operations are divided into geographical segments: United States, Rest of World, and United Kingdom [4]

Core Viewpoint - Indivior PLC has announced its full-year 2026 financial guidance, indicating a strong growth trajectory for its SUBLOCADE product and overall financial performance [2][4]. Financial Guidance - Total net revenue is expected to be in the range of $1,125 million to $1,195 million [4][8]. - Total SUBLOCADE net revenue is projected to be between $905 million and $945 million [4][8]. - Non-GAAP operating expenses are anticipated to be in the range of $430 million to $450 million [4][8]. - Adjusted EBITDA is expected to be between $535 million and $575 million [4][8]. Business Strategy and Highlights - 2025 was identified as a transition year, with the completion of Phase I of the Indivior Action Agenda, focusing on generating momentum through revenue growth and organizational simplification [2][9]. - The company has entered Phase II of the Indivior Action Agenda, which aims to accelerate SUBLOCADE dispense unit growth and net revenue throughout 2026 [2][9]. - Indivior gained inclusion in the S&P SmallCap 600 index effective December 22, 2025 [9]. - The company received shareholder approval to change its domicile from the U.K. to the U.S., with the new U.S. parent company expected to be established by January 26, 2026 [9]. - Indivior has resolved a legacy U.S. Department of Justice matter by paying a total of $295 million [9]. Growth Projections - The company expects SUBLOCADE net revenue growth of 11% at the midpoint of its guidance range [2]. - Adjusted EBITDA is projected to grow by 35%, with an adjusted EBITDA margin increase of 14 percentage points [2].

For my penultimate Barchart article in 2025, I wanted to revisit Indivior (INDV), a Virginia-based developer of opioid addiction treatments that I last covered in early September. At the time, INDV stock had just moved up 11 spots into the top 50 on Barchart’s Top 100 Stocks to Buy list. On Monday, the stock rose 12 spots to 38th, eight places higher than in early fall. More News from Barchart In the past 364 days, Indivior’s share price has risen nearly 200%, with 47% of the gains in the three-plus m ...

Company Overview - Indivior PLC is a specialty pharmaceutical company focused on treating opioid use disorder and related behavioral health conditions, utilizing a diverse portfolio of proprietary therapies and innovative pipeline assets [1] - The company primarily generates revenue through the sale of branded pharmaceutical products, particularly long-acting injectable therapies and sublingual formulations targeting opioid use disorder [2] Financial Performance - In the third quarter, Indivior reported $314 million in revenue, with SUBLOCADE sales increasing by 15% year over year to $219 million, contributing to a 14% rise in adjusted EBITDA to $120 million [5] - Management has raised the full-year 2025 revenue guidance to between $1.18 billion and $1.22 billion, with adjusted EBITDA projected to reach up to $420 million, alongside a plan for at least $150 million in annual operating expense savings starting next year [5] Stock Performance - As of the latest report, Indivior shares were priced at $36.21, reflecting a significant increase of 194% over the past year, outperforming the S&P 500, which rose about 15% during the same period [3] Investor Activity - Stonepine Capital Management sold 250,000 shares of Indivior during the third quarter, resulting in a decrease in the fund's position value by approximately $2.75 million, leaving them with 100,000 shares valued at $2.41 million at quarter-end [4] - The sale appears to be a strategic decision rather than a lack of confidence, as Indivior still represents a meaningful exposure in Stonepine's portfolio relative to other biotech names [6]

Group 1 - Indivior PLC has been added to the S&P SmallCap 600 index, effective December 22, 2025, marking a significant milestone for the company [1][2] - The inclusion in the S&P SmallCap 600 aligns Indivior's capital markets presence with its enhanced U.S. business profile, as stated by the CEO Joe Ciaffoni [2] - The S&P SmallCap 600 index consists of 600 U.S. companies with market capitalizations between $1.2 billion and $8.0 billion, designed to track liquid and financially viable companies [2] Group 2 - Indivior Pharmaceuticals focuses on developing medicines for opioid use disorder (OUD) and aims to transform OUD into a recognized chronic disease [3] - The company is committed to expanding its portfolio of OUD treatments and has a pipeline of product candidates to enhance its offerings in this category [3]

RICHMOND, Va., Dec. 17, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq: INDV) today announced results from a randomized, double-blind clinical trial published in JAMA Network Open. The study found that both the 100-mg and 300-mg monthly maintenance doses of SUBLOCADE® (extended- release buprenorphine) rapidly reduced opioid use and improved opioid abstinence and were well tolerated, with no new safety signals in individuals with moderate-to-severe opioid use disorder (OUD). Participants across both dose groups e ...